Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon
Rechercher Study Connect
  • NCT04947579

Active, Not Recruiting

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis - CC-99677-AS-001

Mis à jour: 9 décembre, 2022   |   ClinicalTrials.gov

Celgene Corporation, filiale entièrement détenue par Bristol-Myers Squibb Company 

Résumé imprimable

VOUS ENVISAGEZ CET ESSAI ?
Imprimer cette page et le guide d’essai pour vous aider à parler avec votre médecin.
Utiliser le Guide du participant à l’étude pour découvrir comment participer à un essai clinique. Comprendre les principaux facteurs à envisager avant de prendre une décision et poser des questions à votre équipe soignante.
Imprimer cette page CC-99677-AS-001
Télécharger le guide du participant à l’étude

SÉLECTIONNER LA LANGUE

Détails de l’essai

  • Phase 2

    Phase

  • Sexe(s)

  • 18-65

    Tranche d’âge

  • Active, Not Recruiting

Options de traitement

Bras de l’étude
INTERVENTION ASSIGNÉE
Experimental: Administration of CC-99677 150 mg QD PO
Drug: CC-99677
Experimental: Administration of CC-99677 150 mg QD PO.
Drug: CC-99677
Experimental: Administration of CC-99677 60mg QD PO
Drug: CC-99677
Experimental: Administration of CC-99677 60mg QD PO.
Drug: CC-99677
Placebo Comparator: Administration of Placebo QD PO
Other: Placebo
Placebo Comparator: Placebo additional dose cohort
Other: Placebo

Principaux critères d’éligibilité

Inclusion Criteria: - Diagnosis of Ankylosing Spondylitis (AS) fulfilling the modified New York criteria - Active axial disease at Screening and Baseline defined by a Bath Ankylosing - Spondylitis Disease Activity Index (BASDAI) score ≥ 4 and Total Back Pain ≥ 4 - Failed prior treatment with at least 2 NSAIDs for at least 4 weeks each - Participant has never received a biologic therapy eg, tumor necrosis factor (TNF) antagonist or monoclonal antibody [mAb] against IL-17A (biologic naive main study), or have taken more than one biologic therapy (biologic-failure substudy) for the treatment of AS Exclusion Criteria: - Radiographic evidence of total ankylosis of the spine - Clinically significant back pain caused by diseases other than AS - Concurrent treatment or treatment within the 6 months prior to Baseline with cell depleting biologic agents - Participation in any study of an investigational drug, including those for COVID-19 - History of malignancy - Oral corticosteroids (prednisone or equivalent) > 10 mg/day systemically for ≥ 2 weeks prior to Baseline Visit

Nous vous recommandons vivement de contacter BMS pour signaler les effets secondaires (événements indésirables)
Les effets secondaires (événements indésirables) et les autres événements à signaler sont définis ici
Signaler des plaintes concernant des effets indésirables (effets indésirables) ou des produits: Informations médicales